Ellen J. Gordon, Ph.D. and Julie DiPopolo Ph.D. will present “How Halos and Themes Distort Brand Messages and Prescriber Uptake” at the 2018 Intellus Institute.
RG+A announces the addition of four new team members to support its 2018 growth strategy. The recent additions expand RG+A’s client service, sales, and marketing science functions.
Continuing its annual tradition of helping to make the community greener, RG+A aided in replanting efforts at Tyler State Park in Bucks County, PA
Join RG+A as we explore the latest insights from our experts in our quarterly newsletter.
Following recent news regarding Facebook’s data misuse and confirmed FTC investigation, RG+A will shut down its company Facebook page as of 5:00p EDT today.
Workshop: Providers & Patients – Traveling the Path to Cancer Therapy Together, Roger Green, RG+A & Chaitra Ujjani, M.D., Georgetown University Hospital
Complex diseases present particular challenges in identifying inflection points for treatment decisions. When considering extended treatment over multiple lines of therapy – as is the case in most cancer treatment – triggers of physician treatment decisions become even more difficult to unravel.
In this workshop attendees will be challenged to think differently about how research might be constructed and executed if patients, rather than physicians, are the center of focus.
Further enhancing its position as the foremost provider of strategic research solutions in healthcare, RG+A has appointed Ellen Gordon as Senior Vice President and Head of Research.
We will discuss “Line of Therapy” treatment simulation methodology, an innovation that allows researchers to forecast the next five years of market development in these disease classes.
RG+A has recently implemented some key staffing changes to support the company’s ongoing growth in its biopharma forecasting and device/diagnostics lines of business.
Join us as we present at PRMG Connect in Orlando, FL!
In this workshop, you will learn how to design and build models quickly and efficiently while managing the statistical error inherent in any forward-looking exercise. The workshop itself will combine didactic learning with group exercises to provide a sense of critical success factors in building models under uncertainty and offer a couple of specific tricks you can use in organizing the process.
Complex Diseases: Challenges in Forecasting Physician Treatment Decisions under Multiple Market Scenarios
In this session, we will focus on some of the common assumptions marketers and researchers make that can lead to models, strategies and product positions that are simply wrong, and how to avoid the assumptions that lead to these errors. The presenters will build on RG+A’s extensive history in market simulation and modeling, including errors we have seen, to provide some simple benchmarks for building better forecasts and support tools.
According to members of RG+A’s Health Payer Council® (HPC®), an online community of managed care pharmacy and medical directors, biosimilar products are likely to continue to face the same scrutiny and pricing pressure from payers as their innovator counterparts, as well as competition from other biosimilar products.